These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 16832586)

  • 1. Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.
    Correa-Silva SR; Nascif SO; Lengyel AM
    Pituitary; 2006; 9(2):101-7. PubMed ID: 16832586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6).
    Correa-Silva SR; Nascif SO; Molica P; Sá LB; Vieira JG; Lengyel AM
    Clin Endocrinol (Oxf); 2010 Jan; 72(1):70-5. PubMed ID: 19453623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment.
    Molica P; Nascif SO; Correa-Silva SR; de Sá LB; Vieira JG; Lengyel AM
    Pituitary; 2010 Dec; 13(4):315-23. PubMed ID: 20602173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus.
    de Sá LB; Nascif SO; Correa-Silva SR; Molica P; Vieira JG; Dib SA; Lengyel AM
    Metabolism; 2010 Oct; 59(10):1536-42. PubMed ID: 20189610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of one month ketoconazole treatment on GH, cortisol and ACTH release after ghrelin, GHRP-6 and GHRH administration in patients with Cushing's disease.
    Correa-Silva SR; Nascif SO; Silva MR; Molica P; Lengyel AM
    Arq Bras Endocrinol Metabol; 2007 Oct; 51(7):1110-7. PubMed ID: 18157387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial restoration of GH responsiveness to ghrelin in Cushing's disease after 6 months of ketoconazole treatment: comparison with GHRP-6 and GHRH.
    Correa-Silva SR; Nascif SO; Molica P; Sá LB; Vieira JG; Lengyel AM
    Eur J Endocrinol; 2009 Nov; 161(5):681-6. PubMed ID: 19696160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism.
    Borges MH; DiNinno FB; Lengyel AM
    Clin Endocrinol (Oxf); 1997 Jun; 46(6):713-8. PubMed ID: 9274702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ghrelin is no longer able to stimulate growth hormone secretion in patients with Cushing's syndrome but instead induces exaggerated corticotropin and cortisol responses.
    Leal-Cerro A; Torres E; Soto A; Dios E; Deghenghi R; Arvat E; Ghigo E; Dieguez C; Casanueva FF
    Neuroendocrinology; 2002 Dec; 76(6):390-6. PubMed ID: 12566947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome.
    Leal-Cerro A; Pumar A; Garcia-Garcia E; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):649-54. PubMed ID: 7828354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
    Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease.
    Arvat E; Ramunni J; Giordano R; Maccagno B; Broglio F; Benso A; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1999 Jan; 22(1):23-8. PubMed ID: 10090133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.
    Nascif SO; Correa-Silva SR; Silva MR; Lengyel AM
    Pituitary; 2007; 10(1):27-33. PubMed ID: 17410412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of growth hormone-releasing peptides in healthy dogs and in dogs with pituitary-dependent hyperadrenocorticism.
    Bhatti SF; De Vliegher SP; Van Ham L; Kooistra HS
    Mol Cell Endocrinol; 2002 Nov; 197(1-2):97-103. PubMed ID: 12431802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide.
    Rigamonti AE; Bonomo SM; Cella SG; Müller EE
    J Endocrinol; 2002 Sep; 174(3):387-94. PubMed ID: 12208658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of growth hormone secretagogues on the release of adenohypophyseal hormones in young and old healthy dogs.
    Bhatti SF; Duchateau L; Van Ham LM; De Vliegher SP; Mol JA; Rijnberk A; Kooistra HS
    Vet J; 2006 Nov; 172(3):515-25. PubMed ID: 15951209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
    Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between tumoral GH-releasing peptide receptor type 1a mRNA expression and in vivo response to GH-releasing peptide-6 in ACTH-dependent Cushing's syndrome patients.
    Machado MC; Valeria de Sa S; Correa-Giannella ML; Giorgi RR; Pereira MA; Cescato VA; Giannella-Neto D; Salgado LR
    Eur J Endocrinol; 2008 May; 158(5):605-13. PubMed ID: 18426818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma.
    Arvat E; Giordano R; Ramunni J; Arnaldi G; Colao A; Deghenghi R; Lombardi G; Mantero F; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4207-11. PubMed ID: 9851753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine responses to ghrelin in adult patients with isolated childhood-onset growth hormone deficiency.
    Aimaretti G; Baffoni C; Broglio F; Janssen JA; Corneli G; Deghenghi R; van der Lely AJ; Ghigo E; Arvat E
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):765-71. PubMed ID: 12072046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.